SARS-CoV-2 vaccine produces strong antibody response in IBD patients

A comprehensive review of data showed that two doses of a SARS-CoV-2 vaccine were safe and effective in patients with inflammatory bowel disease, according to a report in Alimentary Pharmacology & Therapeutics.“The efficacy of the SARS-CoV-2 vaccines has been demonstrated in several clinical trials; however, patients with IBD or those treated with immunosuppressive medications were excluded from these studies,” Abhishek Bhurwal, MD, of the division of gastroenterology and hepatology at Rutgers Robert Wood Johnson School of Medicine, and colleagues wrote. “Therefore,Read More

Related Articles